For citations:
. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012;5(2):3-8. (In Russ.)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Fullscreen
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Popular articles
Vol 10, No 1 (2017)
Vol 17, No 3 (2024)
Vol 16, No 3 (2023)
Vol 16, No 4 (2023)
Vol 18, No 1 (2025)
Vol 13, No 1 (2020)
Article Tools
Email this article (Login required)
Email the author (Login required)
Email this article (Login required)
Email the author (Login required)
About the Author
Keywords
COVID-19
NAFLD
budget impact
budget impact analysis
chemotherapy
children
chondroitin sulfate
clinical and economic analysis
cost minimization analysis
cost-effectiveness analysis
cost-utility analysis
drug supply
drugs
evidence-based medicine
glucosamine sulfate
health technology assessment
pharmacoeconomic analysis
pharmacoeconomics
pharmacoepidemiology
pharmacoinformatics
quality of life
Publisher: IRBIS LLC
24 Chechersky St., Moscow 117042
Phone: +7 (495) 649 54 95
Email: digevskaya@irbis-1.ru
